| Year |
Citation |
Score |
| 2010 |
Balliet RM, Chen G, Dellinger RW, Lazarus P. UDP-glucuronosyltransferase 1A10: activity against the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol, and a potential role for a novel UGT1A10 promoter deletion polymorphism in cancer susceptibility. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 38: 484-90. PMID 20007297 DOI: 10.1124/Dmd.109.030569 |
0.411 |
|
| 2009 |
Olson KC, Dellinger RW, Zhong Q, Sun D, Amin S, Spratt TE, Lazarus P. Functional characterization of low-prevalence missense polymorphisms in the UDP-glucuronosyltransferase 1A9 gene. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 37: 1999-2007. PMID 19589876 DOI: 10.1124/Dmd.108.024596 |
0.389 |
|
| 2009 |
Balliet RM, Chen G, Gallagher CJ, Dellinger RW, Sun D, Lazarus P. Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype. Cancer Research. 69: 2981-9. PMID 19318555 DOI: 10.1158/0008-5472.Can-08-4143 |
0.409 |
|
| 2008 |
Chen G, Dellinger RW, Gallagher CJ, Sun D, Lazarus P. Identification of a prevalent functional missense polymorphism in the UGT2B10 gene and its association with UGT2B10 inactivation against tobacco-specific nitrosamines. Pharmacogenetics and Genomics. 18: 181-91. PMID 18300939 DOI: 10.1097/Fpc.0B013E3282F4Dbdd |
0.311 |
|
| 2008 |
Chen G, Dellinger RW, Sun D, Spratt TE, Lazarus P. Glucuronidation of tobacco-specific nitrosamines by UGT2B10. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 36: 824-30. PMID 18238858 DOI: 10.1124/Dmd.107.019406 |
0.353 |
|
| 2007 |
Chen G, Blevins-Primeau AS, Dellinger RW, Muscat JE, Lazarus P. Glucuronidation of nicotine and cotinine by UGT2B10: loss of function by the UGT2B10 Codon 67 (Asp>Tyr) polymorphism. Cancer Research. 67: 9024-9. PMID 17909004 DOI: 10.1158/0008-5472.Can-07-2245 |
0.318 |
|
| 2007 |
Sun D, Sharma AK, Dellinger RW, Blevins-Primeau AS, Balliet RM, Chen G, Boyiri T, Amin S, Lazarus P. Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 35: 2006-14. PMID 17664247 DOI: 10.1124/Dmd.107.017145 |
0.359 |
|
| 2007 |
Dellinger RW, Chen G, Blevins-Primeau AS, Krzeminski J, Amin S, Lazarus P. Glucuronidation of PhIP and N-OH-PhIP by UDP-glucuronosyltransferase 1A10. Carcinogenesis. 28: 2412-8. PMID 17638922 DOI: 10.1093/Carcin/Bgm164 |
0.365 |
|
| 2006 |
Sun D, Chen G, Dellinger RW, Duncan K, Fang JL, Lazarus P. Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants. Breast Cancer Research : Bcr. 8: R50. PMID 16884532 DOI: 10.1186/Bcr1539 |
0.326 |
|
| 2006 |
Dellinger RW, Fang JL, Chen G, Weinberg R, Lazarus P. Importance of UDP-glucuronosyltransferase 1A10 (UGT1A10) in the detoxification of polycyclic aromatic hydrocarbons: decreased glucuronidative activity of the UGT1A10139Lys isoform. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 34: 943-9. PMID 16510539 DOI: 10.1124/Dmd.105.009100 |
0.384 |
|
| 2003 |
Dellinger RW, Karjian PL, Neuteboom ST. NB1011 induces Ser15 phosphorylation of p53 and activates the G2/M checkpoint. Anti-Cancer Drugs. 14: 449-55. PMID 12853888 DOI: 10.1097/00001813-200307000-00011 |
0.486 |
|
| 2003 |
Barnes EA, Porter LA, Lenormand JL, Dellinger RW, Donoghue DJ. Human Spy1 promotes survival of mammalian cells following DNA damage. Cancer Research. 63: 3701-7. PMID 12839962 |
0.542 |
|
| 2002 |
Porter LA, Dellinger RW, Tynan JA, Barnes EA, Kong M, Lenormand JL, Donoghue DJ. Human Speedy: a novel cell cycle regulator that enhances proliferation through activation of Cdk2. The Journal of Cell Biology. 157: 357-66. PMID 11980914 DOI: 10.1083/Jcb.200109045 |
0.575 |
|
| 1999 |
Lenormand JL, Dellinger RW, Knudsen KE, Subramani S, Donoghue DJ. Speedy: a novel cell cycle regulator of the G2/M transition. The Embo Journal. 18: 1869-77. PMID 10202150 DOI: 10.1093/Emboj/18.7.1869 |
0.575 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2012 |
Dellinger RW, Matundan HH, Ahmed AS, Duong PH, Meyskens FL. Anti-cancer drugs elicit re-expression of UDP-glucuronosyltransferases in melanoma cells. Plos One. 7: e47696. PMID 23110092 DOI: 10.1371/Journal.Pone.0047696 |
0.299 |
|
| 2014 |
Dellinger RW, Garcia AMG, Meyskens FL. Differences in the glucuronidation of resveratrol and pterostilbene: Altered enzyme specificity and potential gender differences Drug Metabolism and Pharmacokinetics. 29: 112-119. PMID 23965644 DOI: 10.2133/Dmpk.Dmpk-13-Rg-012 |
0.229 |
|
| 2016 |
Dellinger RW, Meyskens FL. Detection of Total UDP-Glucuronosyltransferase (UGT) Activity in Melanoma Cells. Methods in Molecular Biology (Clifton, N.J.). PMID 26786882 DOI: 10.1007/7651_2015_298 |
0.216 |
|
| 2010 |
Sun D, Chen G, Dellinger RW, Sharma AK, Lazarus P. Characterization of 17-dihydroexemestane glucuronidation: potential role of the UGT2B17 deletion in exemestane pharmacogenetics. Pharmacogenetics and Genomics. 20: 575-85. PMID 20697310 DOI: 10.1097/Fpc.0B013E32833B04Af |
0.211 |
|
| 2022 |
Fels JA, Casalena G, Konrad C, Holmes HE, Dellinger RW, Manfredi G. Gene expression profiles in sporadic ALS fibroblasts define disease subtypes and the metabolic effects of the investigational drug EH301. Human Molecular Genetics. PMID 35652455 DOI: 10.1093/hmg/ddac118 |
0.183 |
|
| 2018 |
Obrador E, Liu-Smith F, Dellinger RW, Salvador R, Meyskens FL, Estrela JM. Oxidative stress and antioxidants in the pathophysiology of malignant melanoma. Biological Chemistry. PMID 30352021 DOI: 10.1515/Hsz-2018-0327 |
0.169 |
|
| 2018 |
Laquer V, Dellinger RW, Mannering I, Garcia AG, Abraham V, Pavlis J, Liu-Smith F, De Feraudy S, Meyskens FL, Kelly KM. 12-hydroxyeicosatetraenoic acid (12-HETE) levels are increased in Actinic Keratoses (AK) and Squamous Cell Carcinoma (SCC). Journal of the American Academy of Dermatology. PMID 29902547 DOI: 10.1016/J.Jaad.2018.05.1251 |
0.165 |
|
| 2021 |
Obrador E, Salvador-Palmer R, Jihad-Jebbar A, López-Blanch R, Dellinger TH, Dellinger RW, Estrela JM. Pterostilbene in Cancer Therapy. Antioxidants (Basel, Switzerland). 10. PMID 33801098 DOI: 10.3390/antiox10030492 |
0.146 |
|
| 2014 |
Liu-Smith F, Dellinger R, Meyskens FL. Updates of reactive oxygen species in melanoma etiology and progression. Archives of Biochemistry and Biophysics. 563: 51-5. PMID 24780245 DOI: 10.1016/J.Abb.2014.04.007 |
0.141 |
|
| 2014 |
Liu-Smith F, Dellinger R, Meyskens FL. Updates of reactive oxygen species in melanoma etiology and progression Archives of Biochemistry and Biophysics. 563: 51-55. DOI: 10.1016/j.abb.2014.04.007 |
0.14 |
|
| 2017 |
Estrela JM, Mena S, Obrador E, Benlloch M, Castellano G, Salvador R, Dellinger RW. Polyphenolic Phytochemicals in Cancer Prevention and Therapy: Bioavailability versus Bioefficacy. Journal of Medicinal Chemistry. PMID 28654265 DOI: 10.1021/acs.jmedchem.6b01026 |
0.133 |
|
| 2016 |
Mukherjee S, Chellappa K, Moffitt A, Ndungu J, Dellinger RW, Davis JG, Agarwal B, Baur JA. Nicotinamide adenine dinucleotide biosynthesis promotes liver regeneration. Hepatology (Baltimore, Md.). PMID 27809334 DOI: 10.1002/hep.28912 |
0.121 |
|
| 2016 |
Trammell SA, Schmidt MS, Weidemann BJ, Redpath P, Jaksch F, Dellinger RW, Li Z, Abel ED, Migaud ME, Brenner C. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nature Communications. 7: 12948. PMID 27721479 DOI: 10.1038/Ncomms12948 |
0.119 |
|
| 2023 |
López-Blanch R, Salvador-Palmer R, Oriol-Caballo M, Moreno-Murciano P, Dellinger RW, Estrela JM, Obrador E. Nicotinamide riboside, pterostilbene and ibudilast protect motor neurons and extend survival in ALS mice. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 21: e00301. PMID 38241160 DOI: 10.1016/j.neurot.2023.10.011 |
0.117 |
|
| 2023 |
Dhuguru J, Dellinger RW, Migaud ME. Defining NAD(P)(H) Catabolism. Nutrients. 15. PMID 37447389 DOI: 10.3390/nu15133064 |
0.113 |
|
| 2016 |
Frederick DW, Loro E, Liu L, Davila A, Chellappa K, Silverman IM, Quinn WJ, Gosai SJ, Tichy ED, Davis JG, Mourkioti F, Gregory BD, Dellinger RW, Redpath P, Migaud ME, et al. Loss of NAD Homeostasis Leads to Progressive and Reversible Degeneration of Skeletal Muscle. Cell Metabolism. 24: 269-282. PMID 27508874 DOI: 10.1016/J.Cmet.2016.07.005 |
0.105 |
|
| 2017 |
Dellinger RW, Santos SR, Morris M, Evans M, Alminana D, Guarente L, Marcotulli E. Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD+ levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study. Npj Aging and Mechanisms of Disease. 3: 17. PMID 29184669 DOI: 10.1038/s41514-017-0016-9 |
0.092 |
|
| 2014 |
Dellinger RW, Liu-Smith F, Meyskens FL. Continuing to illuminate the mechanisms underlying UV-mediated melanomagenesis. Journal of Photochemistry and Photobiology. B, Biology. 138: 317-23. PMID 25022944 DOI: 10.1016/J.Jphotobiol.2014.06.006 |
0.091 |
|
| 2011 |
Matundan HH, Dellinger RW, Meyskens FL. Nrf2 Mediates Chemoresistance in Melanoma Free Radical Biology and Medicine. 51: S126. DOI: 10.1016/J.Freeradbiomed.2011.10.330 |
0.084 |
|
| 2020 |
Simic P, Vela Parada XF, Parikh SM, Dellinger R, Guarente LP, Rhee EP. Nicotinamide riboside with pterostilbene (NRPT) increases NAD in patients with acute kidney injury (AKI): a randomized, double-blind, placebo-controlled, stepwise safety study of escalating doses of NRPT in patients with AKI. Bmc Nephrology. 21: 342. PMID 32791973 DOI: 10.1186/s12882-020-02006-1 |
0.083 |
|
| 2018 |
Dellinger RW, Santos SR, Morris M, Evans M, Alminana D, Guarente L, Marcotulli E. Erratum: Author Correction: Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study. Npj Aging and Mechanisms of Disease. 4: 8. PMID 30155270 DOI: 10.1038/s41514-018-0027-1 |
0.083 |
|
| 2022 |
Jensen JB, Dollerup OL, Møller AB, Billeskov TB, Dalbram E, Chubanava S, Damgaard MV, Dellinger RW, Trošt K, Moritz T, Ringgaard S, Møller N, Treebak JT, Farup J, Jessen N. A randomized placebo-controlled trial of nicotinamide riboside+pterostilbene supplementation in experimental muscle injury in elderly subjects. Jci Insight. PMID 35998039 DOI: 10.1172/jci.insight.158314 |
0.075 |
|
| 2020 |
Marinescu AG, Chen J, Holmes HE, Guarente L, Mendes O, Morris M, Dellinger RW. Safety Assessment of High-Purity, Synthetic Nicotinamide Riboside (NR-E) in a 90-Day Repeated Dose Oral Toxicity Study, With a 28-Day Recovery Arm. International Journal of Toxicology. 39: 307-320. PMID 32715855 DOI: 10.1177/1091581820927406 |
0.067 |
|
| 2022 |
Damgaard MV, Nielsen TS, Basse AL, Chubanava S, Trost K, Moritz T, Dellinger RW, Larsen S, Treebak JT. Intravenous nicotinamide riboside elevates mouse skeletal muscle NAD without impacting respiratory capacity or insulin sensitivity. Iscience. 25: 103863. PMID 35198907 DOI: 10.1016/j.isci.2022.103863 |
0.06 |
|
| 2019 |
de la Rubia JE, Drehmer E, Platero JL, Benlloch M, Caplliure-Llopis J, Villaron-Casales C, de Bernardo N, AlarcÓn J, Fuente C, Carrera S, Sancho D, GarcÍa-Pardo P, Pascual R, JuÁrez M, Cuerda-Ballester M, ... ... Dellinger RW, et al. Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 1-8. PMID 30668199 DOI: 10.1080/21678421.2018.1536152 |
0.055 |
|
| 2022 |
Obrador E, Salvador-Palmer R, Pellicer B, López-Blanch R, Sirerol JA, Villaescusa JI, Montoro A, Dellinger RW, Estrela JM. Combination of natural polyphenols with a precursor of NAD and a TLR2/6 ligand lipopeptide protects mice against lethal γ radiation. Journal of Advanced Research. PMID 35599107 DOI: 10.1016/j.jare.2022.05.005 |
0.054 |
|
| 2021 |
Obrador E, Salvador-Palmer R, López-Blanch R, Dellinger RW, Estrela JM. NAD Precursors and Antioxidants for the Treatment of Amyotrophic Lateral Sclerosis. Biomedicines. 9. PMID 34440204 DOI: 10.3390/biomedicines9081000 |
0.053 |
|
| 2022 |
Dellinger RW, Holmes HE, Hu-Seliger T, Butt RW, Harrison SA, Mozaffarian D, Chen O, Guarente L. NRPT reduces markers of hepatic inflammation in non-alcoholic fatty liver disease: a double-blind, placebo-controlled clinical trial. Hepatology (Baltimore, Md.). PMID 36082508 DOI: 10.1002/hep.32778 |
0.052 |
|
| 1974 |
Cadman TW, Dellinger RW. Techniques for removing metals from process wastewater Chemical Engineering (New York). 81: 79-85. |
0.013 |
|
| Hide low-probability matches. |